Amid a sideways-trending overall stock market, the stock price of healthcare giant Johnson & Johnson (JNJ) has shown a strong upward trend this month. This performance is primarily attributed to a series of positive developments surrounding the company, which have successfully boosted market confidence.
At the beginning of the month, Johnson & Johnson’s stock experienced a period of weakness but subsequently surged driven by positive factors. Investors had already reacted positively to the company’s third-quarter earnings report released in October, which showed slightly better-than-expected earnings and raised full-year guidance. As the month progressed, positive news continued to emerge. Johnson & Johnson successively received label expansion approvals from the U.S. Food and Drug Administration (FDA) for several of its drugs, including the antidepressant Caplyta and the multiple myeloma treatment Darzalex Faspro. This indicates further enhanced market potential and revenue expectations for the related products.
Meanwhile, a major acquisition plan has also strengthened investor optimism. Johnson & Johnson announced it would acquire the private biotechnology company Halda Therapeutics for $3.05 billion in an all-cash transaction. Halda Therapeutics is the developer of the prostate cancer drug HLD-0915. This acquisition will significantly strengthen Johnson & Johnson’s research pipeline in the field of oncology treatment, injecting new momentum for its long-term growth.
Regarding the future outlook for Johnson & Johnson’s stock, it remains uncertain whether the short-term strong momentum can continue into next month and beyond. However, as a blue-chip stock, investment in it should focus more on long-term value rather than short-term trading trends. Looking back over the past decade, although Johnson & Johnson’s performance has sometimes lagged behind major indices like the S&P 500, the company is undergoing business adjustments, such as spinning off the slower-growing orthopaedics business and focusing more on the faster-growing pharmaceutical and healthcare sectors. This suggests the next decade might be different. Furthermore, the company has increased its dividend for 63 consecutive years, boasting an exceptional dividend growth record. The most recent increase was 4.8%, and based on the current stock price, its forward dividend yield is approximately 2.5%. This is expected to contribute significant returns for long-term investors.
